眼科局所治療薬は、予測期間（2023年から2030年）中に7.25％という大幅なCAGRを記録すると推定されます。この市場は、高齢者人口の増加や眼科疾患の蔓延の拡大など、いくつかの要因によって推進されています。屈折異常、ドライアイ、緑内障、目の過敏症、加齢黄斑変性症などの眼科の問題が世界的に増加しており、これが市場の拡大を推進しています。WHO によると、2021 年 10 月、 世界中で約 22 億人が視力低下による悪影響を経験しています。
Public Glaucoma Exploration が示しているように、300 万人を超えるアメリカ人が緑内障を患っています。 WHO によると、2021 年時点で世界中で 770 万人を超える人が緑内障の悪影響を経験しています。緑内障の最も広く認識されている治療法は、緑内障の悪化を抑えることができるベータ遮断薬、プロスタグランジン、Rhoキナーゼ阻害薬などの治療用点眼薬です。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISE IN GERIATRIC POPULATION
4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
4.4 OPPORTUNITIES
4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTTION
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 ARTIFICIAL TEARS
6.3 ANTI-ALLERGY
6.4 ANTIBIOTIC DROPS
6.5 ANTI-INFLAMMATORY
6.6 ANTIGLAUCOMA
6.7 OTHERS
7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 DRY EYE
7.3 EYE ALLERGY
7.4 GLAUCOMA
7.5 EYE INFECTION
7.6 RETINAL DISORDERS
7.7 UVEITIS
7.8 OTHERS
8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 EYE DROPS
8.3 GELS
8.4 OINTMENTS
8.5 OTHERS
9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 ONLINE PHARMACIES
9.5 OTHERS
10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
11.6.2 PARTNERSHIP/COLLABORATION
11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
11.6.4 MERGERS & ACQUISITIONS
11.7 MAJOR PLAYERS SALES ANALYSIS
11.7.1 SALES & OPERATING INCOME
11.8 MAJOR PLAYERS R&D ANALYSIS
12 COMPANY PROFILES
12.1 SANTEN PHARMACEUTICAL CO., LTD.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIES
12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 NOVARTIS AG
12.3.1 COMPANY OVERVIEWS
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 BAUSCH & LOMB INCORPORATED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 AMNEAL PHARMACEUTICALS LLC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL ANALYSIS
12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 ALCON
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 AKORN OPERATING COMPANY LLC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 VIATRIS INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
